Actovegin, 40 mg/ml 2 ml 25 pcs

Actovegin is an antihypoxant. Actovegin® is a hemoderivative which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 Da pass through).

Positively affects glucose transport and utilization, stimulates oxygen consumption (which leads to stabilization of plasma cell membranes during ischemia and reduction of lactate formation) and thus has an antihypoxic effect, which begins to appear within 30 minutes after oral administration and reaches a maximum in average 3 hours (2-6 hours).

Actovegin® increases concentrations of ATP, ADP, phosphocreatine, and the amino acids glutamate, aspartate and GABA.

The effects of Actovegin® on oxygen uptake and utilization as well as insulin-like activity with stimulation of glucose transport and oxidation are significant in the treatment of diabetic polyneuropathy (DPN).

In patients with diabetes mellitus and DPN, Actovegin® significantly reduces symptoms of polyneuropathy (stabbing pain, burning sensation, paresthesias, and numbness in the lower extremities).

The sensory disturbances are objectively reduced and patients’ mental well-being is improved.

Indications

metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury);
peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers);
wound healing (ulcers of various etiologies, trophic disorders /bedsores/, burns, impaired wound healing processes);
prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy.

Pharmacological effect

Actovegin is an antihypoxant. Actovegin® is a hemoderivative, which is obtained through dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 Da pass through).

It has a positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to the stabilization of plasma membranes of cells during ischemia and a decrease in the formation of lactate), and thus has an antihypoxic effect, which begins to manifest itself no later than 30 minutes after oral administration and reaches a maximum after an average of 3 hours (2–6 hours).

Actovegin® increases the concentrations of ATP, ADP, phosphocreatine, as well as amino acids – glutamate, aspartate and GABA.

The effect of Actovegin® on the absorption and utilization of oxygen, as well as insulin-like activity with stimulation of glucose transport and oxidation are significant in the treatment of diabetic polyneuropathy (DPN).

In patients with diabetes mellitus and DPN, Actovegin® significantly reduces the symptoms of polyneuropathy (stabbing pain, burning sensation, paresthesia, numbness in the lower extremities).

Sensitivity disorders are objectively reduced and the mental well-being of patients is improved.

Special instructions

With repeated administrations of the solution for infusion, the water-electrolyte balance of the blood plasma should be monitored.

The infusion solution and solution for injection have a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not adversely affect the activity of the drug or its tolerability.

Do not use a solution that is opaque or contains foreign particles. After opening the bottle (ampoule), the solution cannot be stored.

In the case of intramuscular administration, the drug is administered slowly, no more than 5 ml. Due to the possibility of an anaphylactic reaction, a test injection (2 ml IM) is recommended.

Active ingredient

Deproteinized hemoderivative of calf blood

Composition

1 ampoule contains:

active ingredient:

Actovegin® concentrate (in terms of dry deproteinized hemoderivative of calf blood)1) – 80.0 mg;

excipient:

water for injection – up to 2 ml.

Pregnancy

The use of Actovegin during pregnancy did not have a negative effect on the mother or fetus, however, if it is necessary to use the drug during pregnancy, the potential risk to the fetus should be taken into account.

Contraindications

hypersensitivity to the drug Actovegin® or similar drugs.
decompensated heart failure;
pulmonary edema;
oliguria;
anuria;
fluid retention in the body.

Side Effects

Allergic reactions:

skin rash;
skin hyperemia;
hyperthermia, up to anaphylactic shock.

Interaction

Currently unknown.

However, in order to avoid possible pharmaceutical incompatibility, it is not recommended to add other drugs to the Actovegin® infusion solution.

Overdose

Information on overdose of the drug Actovegin is not provided.

Storage conditions

In a place protected from light, at a temperature of 18–25 °C

Shelf life

2 years

Manufacturer

Takeda Pharmaceuticals LLC, Russia